en · de · es · pt
melanotan-2-notes.peptides8425.com › Wiki › Melanotan-2 Identity And Receptor Pharmacology — Questions and Answers

Melanotan-2 Identity And Receptor Pharmacology — Questions and Answers

By Editorial Desk · published 2026-07-13 · last reviewed 2026-08-01 · Wiki

cyclic heptapeptide raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.

Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.

Melanotan-2 Identity and Receptor Pharmacology

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.

Chemical Background and Receptor Activity

Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.

Melanotan-2 at a glance

PropertyValueNotes
Common synonymsMelanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amideNaming follows peptide convention; the numeral distinguishes it from melanotan-1
Molecular formulaC50H69N15O9Includes the lactam bridge; no counter-ion assumed
Monoisotopic mass1023.53 DaFree base; salts and counter-ions shift the observed value
AppearanceWhite to off-white lyophilised powderBatch-to-batch colour variation is not itself proof of impurity
Typical analytical methodRP-HPLC purity determination with ESI-MS identity confirmationRetention time alone does not establish sequence identity

Origins and Research Status

The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.

Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.

Related pages on this site

Peptide Identity and Structural Background

Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.

Identity and Chemical Background

The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.

Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.

Melanotan-2 Identity And Regulatory Status

Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.

Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.

Supporting material

=== Measurements of elevated copper status === Although a number of indicators are useful in diagnosing copper deficiency, there are no reliable biomarkers of copper excess resulting from dietary intake. The most reliable indicator of excess copper status is liver copper concentration. However, measurement of this endpoint in humans is intrusive and not generally conducted except in cases of suspected copper poisoning. Increased serum copper or ceruolplasmin levels are not reliably associated with copper toxicity as elevations in concentrations can be induced by inflammation, infection, disease, malignancies, pregnancy, and other biological stressors. Levels of copper-containing enzymes, such as cytochrome c oxidase, superoxide dismutase, and diaminase oxidase, vary not only in response to copper state but also in response to a variety of other physiological and biochemical factors and therefore are inconsistent markers of excess copper status. A new candidate biomarker for copper excess as well as deficiency has emerged in recent years. This potential marker is a chaperone protein, which delivers copper to the antioxidant protein SOD1 (copper, zinc superoxide dismutase). It is called "copper chaperone for SOD1" (CCS), and excellent animal data supports its use as a marker in accessible cells (e.g., erythrocytes) for copper deficiency as well as excess. CCS is currently being tested as a biomarker in humans.

=== Online resale === Buc-ee's does not operate its own online store. However, several third-party resellers offer Buc-ee's products through various platforms, including Amazon, Walmart Marketplace, eBay, Etsy, and dedicated websites such as Texas Snax, True Texas Merch, and Johnny's Goods. These resellers operate under the first-sale doctrine, which permits the resale of legitimately purchased products. Buc-ee's states on its Web site that such resellers "are not affiliated with, authorized, sponsored, or endorsed by Buc-ee's in any way." Texas Snax, founded by Chris J. Koerner in 2020, emerged as one of the largest dedicated Buc-ee's resellers after Koerner initially contacted the company about a partnership and received no response. When Buc-ee's legal team learned of his venture, they permitted it on the condition that he change the original Web site name and add a disclaimer clarifying that Texas Snax is not affiliated with Buc-ee's. Online prices for Buc-ee's products are typically marked up significantly compared to in-store prices.

In response to New York; 50 Cent took aim at both Fat Joe and Jadakiss for their collaboration with Ja Rule on the diss track "Piggy Bank" the following year with the release of his sophomore album The Massacre. Jadakiss responded with the track "Checkmate" six days later, While Fat Joe retaliated with the diss track "My Fofo" on his album All or Nothing three months later.

=== Buoyancy === Due to their environment, aquatic plants experience buoyancy which counteracts their weight. Because of this, their cell covering are far more flexible and soft, due to a lack of pressure that terrestrial plants experience. Green algae are also known to have extremely thin cell walls due to their aquatic surroundings, and research has shown that green algae is the closest ancestor to living terrestrial and aquatic plants. Terrestrial plants have rigid cell walls meant for withstanding harsh weather, as well as keeping the plant upright as the plant resists gravity. Gravitropism, along with phototropism and hydrotropism, are traits believed to have evolved during the transition from an aquatic to terrestrial habitat. Terrestrial plants no longer had unlimited access to water and had to evolve to search for nutrients in their new surroundings as well as develop cells with new sensory functions, such as statocytes.

== Treatment == Treatment is not specific and consists of management of symptoms. Management includes physical therapy for neuropathy and ataxia, educational guidance for writing and reading problems, and speech therapy for dysarthric speech and cognitive impairment. Lipid-lowering agents and low-cholesterol diet might be useed to control cholesterol levels.

Sources: en.wikipedia.org

Notes from published material

It included industrial workers and smallholders, broad middle class (including both the agrarian and urban middle classes), as well as entrepreneurs, civil servants and clerics, and lastly a small but influential group of Catholic aristocracy. The uniting element of the factions of the Centre Party was commitment to Political Catholicism. The party also urged union with Austria. The party had a left wing, represented by politicians such as Constantin Fehrenbach, Matthias Erzberger, Joseph Wirth, as well as Catholic workers' associations and trade unions, led by the Centre's laborist politicians such as Adam Stegerwald. Left-wing factions of the Centre Party were committed to republicanism and pressured the Zentrum to officially identify itself as a pro-republican party; however, the party instead adopted a vague label of being a "constitutional party", which was "ready to collaborate with any legal government". The leftists of the Centre Party also promoted cooperation with the SPD and advised Weimar Catholics to join the Reichsbanner; some left-wing Centre factions were also supportive of cooperation with right-wing nationalist trade unions on pragmatic basis. Along with "republican-democratic" wings of the party, the Centre Party also had socialist factions.

Researchers were able to observe quantum dots in lymph nodes of mice for more than 4 months. Quantum dots can have antibacterial properties similar to nanoparticles and can kill bacteria in a dose-dependent manner. One mechanism by which quantum dots can kill bacteria is through impairing the functions of antioxidative system in the cells and down regulating the antioxidative genes. In addition, quantum dots can directly damage the cell wall. Quantum dots have been shown to be effective against both gram- positive and gram-negative bacteria. Semiconductor quantum dots have also been employed for in vitro imaging of pre-labeled cells. The ability to image single-cell migration in real time is expected to be important to several research areas such as embryogenesis, cancer metastasis, stem cell therapeutics, and lymphocyte immunology. One application of quantum dots in biology is as donor fluorophores in Förster resonance energy transfer, where the large extinction coefficient and spectral purity of these fluorophores make them superior to molecular fluorophores It is also worth noting that the broad absorbance of QDs allows selective excitation of the QD donor and a minimum excitation of a dye acceptor in FRET-based studies. The applicability of the FRET model, which assumes that the Quantum Dot can be approximated as a point dipole, has recently been demonstrated The use of quantum dots for tumor targeting under in vivo conditions employ two targeting schemes: active targeting and passive targeting.

=== Migraine === As of 2024, eight blockers of CGRP or its receptor have been approved by the US Food and Drug Administration for the treatment or prevention of migraine. These include erenumab, brand name Aimovig, approved in the U.S. for use for migraines in 2018. It interacts by blocking the CGRP receptor. As of 2018, fremanezumab, brand name Ajovy, was approved in the U.S. for use for migraines. It interacts with the CGRP protein expressed during an attack. Galcanezumab, brand name Emgality, was the third treatment to be approved in the U.S. in 2018 for use in migraines. It also interacts with the CGRP protein. As of February 2020, eptinezumab (Vyepti) was approved by the FDA for the treatment of migraine via intravenous infusion as well. Three small-molecule antagonists have been approved for treatment of migraine: ubrogepant, rimegepant, and atogepant. Ubrogepant and rimegepant are approved for acute treatment. Atogepant and rimegepant are approved for preventative treatment.

==== Implantation ==== The first cells of the embryo to undergo EMT and form mesenchyme are the extra-embryonic cells of the trophectoderm. These migrate from the body of the blastocyst into the endometrial layer of the uterus in order to contribute to the formation of the anchored placenta.

Sources: en.wikipedia.org

Frequently asked questions

What is melanotan-2 chemically?

It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.

How does it differ from the natural hormone?

The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.

Does it hold any regulatory approval?

No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.

What class of compound is melanotan-2?

It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.

Network